Rabeprazole Sodium Delayed Release Tablets
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D220R0061
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
The Defense Logistics Agency (DLA) Troop Support has issued an award notice for the procurement of Rabeprazole Sodium Delayed Release Tablets, under contract number SPE2D2-20-D-0096. This procurement is classified under NAICS Code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further identified by Product Service Code 6505, indicating a focus on drugs and biologicals.
The scope of this award encompasses the supply of Rabeprazole Sodium Delayed Release Tablets in three distinct packaging configurations: 20mg tablets in counts of 30, 90, and 500. These formulations are intended to support the medical and pharmaceutical needs of federal entities, ensuring reliable access to essential gastrointestinal medication.
The place of performance for this contract is Seymour, Indiana, United States. Contractors should note that all manufacturing, delivery, and related activities will be centered in this location, as specified in the notice.
DLA Troop Support, a federal office, serves as the contracting entity for this procurement. Interested parties or those seeking further clarification may contact the primary point of contact, Phyllis Daraio, via email at [email protected] or by phone at 215-737-7941.
This award notice is currently active and was posted on October 16, 2024. The opportunity details, including any attachments, can be accessed through the official SAM.gov listing at https://sam.gov/opp/6003aa6314a541be93f71c2fcec66925/view.
Contractors evaluating this opportunity should ensure their capabilities align with the manufacturing and supply of pharmaceutical preparations, specifically Rabeprazole Sodium Delayed Release Tablets in the specified counts. The requirements are straightforward, focusing on consistent quality, reliable delivery, and adherence to federal standards for pharmaceutical products. No set-aside requirements or special considerations are indicated in the notice. The core elements of this contract—product specifications, place of performance, and contracting entity—will remain constant throughout the contract lifecycle.